Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Lundbeck: Præsentation af årsregnskabet for 2025 (Optagelse)

By Michael FriisHead of Equities
Lundbeck

Vi havde i går fornøjelsen af, at Lundbecks Vice President, Head of Investor Relations, Jens Høyer, præsenterede 2025 helårsresultaterne samt forventningerne til FY 2026, efterfulgt af en Q&A-session.

Regnskabet landede på linje med forventningerne efter et år med tre opjusteringer, og selskabet tager dele af momentum med ind i 2026, hvor der guides for vækst i både toplinje og indtjening, trods øget investeringsniveau i R&D.

Se eller gense eventet her:

FY 2025 event præsentation

Disclaimer: HC Andersen Capital modtager betaling fra Lundbeck for en Digital IR abonnementsaftale. /Michael Friis kl. 10.18, d. 05/02-2026.

Lundbeck is a pharmaceutical company. The greatest focus is found in research on psychiatric and neurotic disorders, which includes the treatment of depression, schizophrenia, Alzheimer's and Parkinson's syndrome. The company conducts research, development and distribution of medicines where the customer base can be found on a global level. The company was originally founded in 1915 and has its headquarters in Valby.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.